tiprankstipranks
Trending News
More News >
Cosmos Holdings (COSM)
:COSM
Advertisement

Cosmos Holdings (COSM) AI Stock Analysis

Compare
182 Followers

Top Page

CO

Cosmos Holdings

(NASDAQ:COSM)

Rating:46Neutral
Price Target:
$0.50
▲(13.64%Upside)
The overall stock score for Cosmos Holdings is primarily influenced by its weak financial performance marked by net losses and negative cash flows. Technical analysis provides neutral insights, while the valuation is hampered by a negative P/E ratio. The absence of earnings call data and notable corporate events leaves the focus on financial and technical aspects.

Cosmos Holdings (COSM) vs. SPDR S&P 500 ETF (SPY)

Cosmos Holdings Business Overview & Revenue Model

Company DescriptionCosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyCosmos Holdings generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the distribution of branded and generic medications to pharmacies, hospitals, and clinics. In addition to its core pharmaceutical offerings, Cosmos Holdings also engages in the sale of nutraceuticals and other health-related products. Strategic partnerships with healthcare providers and distribution networks play a crucial role in broadening the company's market reach and enhancing its earnings potential. By leveraging its extensive distribution network and product portfolio, Cosmos Holdings continues to expand its presence in the global healthcare market.

Cosmos Holdings Financial Statement Overview

Summary
Cosmos Holdings faces significant financial hurdles with persistent net losses, shrinking revenue, and negative cash flows. While there are signs of reducing debt, the company's financial health remains strained by operational inefficiencies and a heavy reliance on liabilities.
Income Statement
45
Neutral
Cosmos Holdings' income statement reveals challenges in profitability, with consistent net losses and negative EBIT and EBITDA margins over recent periods. The TTM data shows a slight reduction in revenue, indicating a -1.60% revenue growth rate compared to the previous annual period. Despite some improvement in gross profit margin over the TTM period, the negative net profit margin and declining revenue indicate struggles in operational efficiency and market position.
Balance Sheet
50
Neutral
The balance sheet of Cosmos Holdings shows moderate financial stability with a debt-to-equity ratio stabilizing as stockholders' equity increases. However, high total liabilities and low equity ratios reflect potential solvency concerns. The company has reduced total debt significantly over the TTM period, but the equity ratio remains weak, indicating a heavy reliance on liabilities.
Cash Flow
40
Negative
Cosmos Holdings' cash flow statement highlights ongoing liquidity challenges, with negative free cash flow and operating cash flow over recent periods. The TTM shows a negative free cash flow growth rate of approximately 30.05% compared to the previous year, indicating inefficiencies in cash generation. The operating cash flow to net income ratio remains negative, underscoring persistent cash burn issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue54.43M53.38M50.35M56.24M55.41M
Gross Profit4.31M4.35M5.96M8.33M8.06M
EBITDA-13.92M-17.06M-8.90M-3.82M4.39M
Net Income-16.18M-18.54M-13.83M-7.96M820.79K
Balance Sheet
Total Assets54.31M66.01M68.04M49.43M43.84M
Cash, Cash Equivalents and Short-Term Investments336.25K3.85M20.76M293.18K851.19K
Total Debt11.82M12.42M12.03M27.12M32.04M
Total Liabilities29.78M29.97M28.38M45.05M48.01M
Stockholders Equity24.53M36.04M39.66M4.38M-4.16M
Cash Flow
Free Cash Flow-8.14M-24.80M-15.25M-7.99M-11.62M
Operating Cash Flow-7.72M-15.64M-14.87M-7.10M-11.50M
Investing Cash Flow-798.27K-13.76M-21.50K-826.82K-117.74K
Financing Cash Flow5.05M12.69M35.05M7.27M12.46M

Cosmos Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.44
Price Trends
50DMA
0.45
Negative
100DMA
0.45
Negative
200DMA
0.58
Negative
Market Momentum
MACD
<0.01
Negative
RSI
47.74
Neutral
STOCH
33.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Negative. The current price of 0.44 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.45, and below the 200-day MA of 0.58, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.74 is Neutral, neither overbought nor oversold. The STOCH value of 33.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COSM.

Cosmos Holdings Risk Analysis

Cosmos Holdings disclosed 10 risk factors in its most recent earnings report. Cosmos Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cosmos Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥347.74B11.06-2.99%2.56%11.77%-10.16%
60
Neutral
$14.62M3.29%-26.17%
49
Neutral
$8.94M-384.98%14.27%87.31%
47
Neutral
$13.31M-7.72%35.25%81.05%
46
Neutral
$12.88M-58.30%
$7.44M-58.27%
43
Neutral
$14.00M-336.65%-28.78%86.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
COSM
Cosmos Holdings
0.44
-0.70
-61.40%
TXMD
TherapeuticsMD
1.15
-0.63
-35.39%
AYTU
Aytu BioScience
2.37
-0.38
-13.82%
SISI
Shineco
0.16
-19.02
-99.17%
FLGC
Flora Growth
0.62
-0.52
-45.61%
BFRI
Biofrontera
0.88
-0.13
-12.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025